Related Experiment Videos
Chemo-radionuclide therapy for thyroid cancer: initial experimental study with cultured cells
Takashi Misaki1, Masahiro Iwata, Yasuhiro Iida
1Department of Nuclear Medicine and Diagnostic Imaging, Kyoto University Graduate School of Medicine, Japan. misan@kuhp.kyoto-u.ac.jp
Annals of Nuclear Medicine
|November 6, 2002
Summary
Combining doxorubicin with radioiodine therapy shows promise for enhancing thyroid cancer treatment. This in vitro study suggests doxorubicin can accelerate the killing of thyroid cancer cells by radioiodine, warranting further clinical investigation.
Area of Science:
- Oncology
- Nuclear Medicine
- Pharmacology
Background:
- Radioiodine therapy is a standard treatment for distant thyroid cancer metastases.
- Its efficacy is limited, with complete cures achieved in only a subset of patients.
- Combining radioiodine with antineoplastic agents may improve treatment outcomes.
Purpose of the Study:
- To evaluate the in vitro efficacy of combining radioiodine therapy with chemotherapy agents.
- To assess the synergistic effects of doxorubicin, cisplatin, and 5-fluorouracil with radioiodine in thyroid cancer cell lines.
Main Methods:
- Four thyroid cancer cell lines were treated with sublethal concentrations of cisplatin, doxorubicin, or 5-fluorouracil.
- Cells were subsequently exposed to Iodine-131 (I-131) for 48 hours.
- Cell survival was quantified using a colorimetric assay measuring succinate dehydrogenase activity.
Main Results:
- All tested chemotherapeutic agents exhibited concentration-dependent cytotoxicity across the four cell lines.
- Sensitivity to I-131 varied among cell lines, with FRO cells showing the greatest damage.
- Combination therapy with doxorubicin and radioiodine demonstrated the most significant cell killing effect.
- In FRO cells, doxorubicin combined with I-131 reduced cell survival more effectively than radioiodine alone or combined with cisplatin or 5-fluorouracil.
Conclusions:
- In vitro studies indicate that doxorubicin can enhance radioiodine's efficacy in eliminating thyroid cancer cells.
- These findings support further research into the clinical relevance and feasibility of this combined therapeutic approach.